$0.7494
-0.0807-9.72%
Last update: Nov 2, 6:32 PM
Coherus Oncology Inc
CHRSNASDAQ
Coherus Oncology (CHRS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Coherus Oncology (CHRS) last issued guidance on January 13, 2025 for fiscal year 2024. The company guided revenue in the range of $255M - $260M for the period.
Compared to prior guidance, Coherus Oncology raised its revenue forecast from a prior range of $49M - $54M.
Coherus Oncology has issued 4 guidance updates between November 6, 2023 and January 13, 2025. During this period, the company raised its outlook 2 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.12 | $-0.27 | $-0.34 | $-0.32 |
| Actual | $-0.19 | $-0.25 | $-0.34 | $-0.33 |
| Surprise | -58.3% | +7.41% | 0.00% | -3.12% |
| Revenue | ||||
| Estimate | $21.6M | $14.3M | $13.7M | $12.9M |
| Actual | $14.3M | $12.3M | $12.7M | $11.6M |
| Surprise | -33.8% | -14.2% | -6.97% | -10.5% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.21 | $-0.22 | $-0.21 | $-0.21 |
| Revenue | ||||
| Consensus | $15.9M | $17.9M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.19 | $-0.12 | -58.3 % |
| Q1 | May 11, 2026 | $-0.25 | $-0.27 | 7.41 % |
| Q4 | Mar 9, 2026 | $-0.34 | $-0.34 | 0.00 % |
| Q3 | Nov 6, 2025 | $-0.33 | $-0.32 | -3.12 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $14.31M | $21.61M | -33.8 % |
| Q1 | May 11, 2026 | $12.31M | $14.35M | -14.2 % |
| Q4 | Mar 9, 2026 | $12.75M | $13.70M | -6.97 % |
| Q3 | Nov 6, 2025 | $11.57M | $12.93M | -10.5 % |
